Cargando…

Oral small-molecule tyrosine kinase 2 and phosphodiesterase 4 inhibitors in plaque psoriasis: a network meta-analysis

BACKGROUND: Orally administered small-molecule drugs including tyrosine kinase 2 (TYK2) inhibitors and phosphodiesterase 4 (PDE4) inhibitors are new candidates for systemic therapy in plaque psoriasis. However, no previous articles evaluated the benefit and risk profile of TYK2 and PDE4 inhibitors i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Yuanyuan, Li, Zhixuan, Wu, Shuwei, Guo, Linghong, Jiang, Xian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272578/ https://www.ncbi.nlm.nih.gov/pubmed/37334353 http://dx.doi.org/10.3389/fimmu.2023.1180170

Ejemplares similares

Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors
por: Martin, George
Publicado: (2023)

Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules
por: Bellinato, Francesco, et al.
Publicado: (2021)

Small molecule tyrosine kinase inhibitors in pancreatic cancer
por: Gupta, Sachin, et al.
Publicado: (2008)

Efficacy and safety profile of phosphodiesterase 4 inhibitor in the treatment of psoriasis: A systematic review and meta-analysis of randomized controlled trials
por: Kang, Qin, et al.
Publicado: (2022)

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
por: Gooderham, Melinda, et al.
Publicado: (2015)

Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors
por: Smith, C. I. Edvard, et al.
Publicado: (2021)

Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways
por: Zhou, Yu, et al.
Publicado: (2022)

Potential of Small Molecule Protein Tyrosine Kinase Inhibitors as Immunomodulators and Inhibitors of the Development of Diabetes
por: Little, Peter J., et al.
Publicado: (2009)

The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials
por: Qiu, Jingyue, et al.
Publicado: (2023)

Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight
por: Hutmacher, MM, et al.
Publicado: (2017)

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
por: Spector, Neil, et al.
Publicado: (2007)

New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitors
por: Lin, Nancy U, et al.
Publicado: (2004)

Treatment Effects of the Second-Generation Tyrosine Kinase Inhibitor Dasatinib on Autoimmune Arthritis
por: Guo, Kai, et al.
Publicado: (2019)

Effect of Tyrosin Kinase Inhibitors on NK Cell and ILC3 Development and Function
por: Damele, Laura, et al.
Publicado: (2018)

Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma
por: Liang, Linjun, et al.
Publicado: (2023)

Phosphodiesterase-4 Inhibition in Psoriasis
por: Milakovic, Milica, et al.
Publicado: (2021)

Advances in small molecule inhibitors for treatment of psoriasis
por: Chen, Wen-Juan, et al.
Publicado: (2021)

Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
por: Hojjat-Farsangi, Mohammad
Publicado: (2014)

A Small Molecule Inhibitor of Bruton’s Tyrosine Kinase Involved in B-Cell Signaling
por: Ratzon, Einav, et al.
Publicado: (2017)

Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis
por: Tan, H, et al.
Publicado: (2013)

Phosphodiesterase 4 inhibitor apremilast improves insulin resistance in psoriasis patients
por: Ikumi, Kyoko, et al.
Publicado: (2021)

Targeting Bruton’s Tyrosine Kinase in CLL
por: Ahn, Inhye E., et al.
Publicado: (2021)

Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome
por: Secombe, Kate R., et al.
Publicado: (2020)

Mode of action of DNA-competitive small molecule inhibitors of tyrosyl DNA phosphodiesterase 2
por: Hornyak, Peter, et al.
Publicado: (2016)

Small Molecule IL-36γ Antagonist as a Novel Therapeutic Approach for Plaque Psoriasis
por: Todorović, Viktor, et al.
Publicado: (2019)

Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response
por: Yang, Fei, et al.
Publicado: (2022)

Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
por: Szilveszter, Kata P., et al.
Publicado: (2019)

Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors
por: Rodrigues-Santos, Paulo, et al.
Publicado: (2018)

Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC
por: Nigro, Annunziata, et al.
Publicado: (2020)

Bioactive Lipids as Chronic Myeloid Leukemia’s Potential Biomarkers for Disease Progression and Response to Tyrosine Kinase Inhibitors
por: de Almeida, Felipe Campos, et al.
Publicado: (2022)

Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?
por: Rendell, Aimee, et al.
Publicado: (2022)

Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial
por: Ohtsuki, Mamitaro, et al.
Publicado: (2017)

Inhibition of receptor tyrosine kinase signalling by small molecule agonist of T-cell protein tyrosine phosphatase
por: Mattila, Elina, et al.
Publicado: (2010)

Microwave ablation and synchronous transarterial chemoembolization combined with PD-1 inhibitor in patients with hepatocellular carcinoma following tyrosine kinase inhibitor intolerance
por: Shi, Qin, et al.
Publicado: (2023)

Editorial: Immunotherapy and small molecule inhibitors as combinational cancer therapeutics
por: Khan, Mohd Wajid Ali, et al.
Publicado: (2023)

Myeloid-Derived Suppressor Cells as Target of Phosphodiesterase-5 Inhibitors in Host-Directed Therapeutics for Tuberculosis
por: Leukes, Vinzeigh, et al.
Publicado: (2020)

Receptor Tyrosine Kinase Inhibitor Sunitinib as Novel Immunotherapy to Inhibit Myeloid-Derived Suppressor Cells for Treatment of Endometriosis
por: He, Ying, et al.
Publicado: (2021)

Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
por: Zhao, Shankun, et al.
Publicado: (2021)

In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy
por: Sanchez, María Belén, et al.
Publicado: (2023)

IL-21 Induces an Imbalance of Th17/Treg Cells in Moderate-to-Severe Plaque Psoriasis Patients
por: Shi, Yuling, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rckbcmv7a5v3mubhouvi9c4u3h